Coloplast A/S (OTCMKTS:CLPBY) Short Interest Update

Coloplast A/S (OTCMKTS:CLPBY) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 60,200 shares, a decrease of 26.6% from the November 15th total of 82,000 shares. Based on an average trading volume of 182,400 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

CLPBY has been the subject of several analyst reports. UBS Group upgraded shares of Coloplast A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday. Hsbc Global Res raised Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research note on Monday, November 18th.

Coloplast A/S Stock Performance

Shares of OTCMKTS CLPBY traded up $0.19 during trading on Friday, reaching $11.68. 433,995 shares of the stock were exchanged, compared to its average volume of 129,173. Coloplast A/S has a twelve month low of $11.08 and a twelve month high of $14.34. The company has a current ratio of 1.02, a quick ratio of 0.56 and a debt-to-equity ratio of 0.92. The business’s 50-day moving average price is $12.71 and its 200 day moving average price is $12.85.

Coloplast A/S (OTCMKTS:CLPBY) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.08 earnings per share for the quarter. Coloplast A/S had a net margin of 18.69% and a return on equity of 30.19%. The firm had revenue of $1.02 billion for the quarter. Equities analysts predict that Coloplast A/S will post 0.37 EPS for the current fiscal year.

Coloplast A/S Increases Dividend

The business also recently declared a dividend, which will be paid on Friday, December 20th. Investors of record on Monday, December 9th will be given a $0.2435 dividend. The ex-dividend date is Monday, December 9th. This is a boost from Coloplast A/S’s previous dividend of $0.05. Coloplast A/S’s dividend payout ratio (DPR) is presently 96.97%.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.